Loskog, Angelica
Maleka, Aglaia
Mangsbo, Sara
Svensson, Emma
Lundberg, Christina
Nilsson, Anders
Krause, Johan
Agnarsdóttir, Margrét
Sundin, Anders
Ahlström, Håkan
Tötterman, Thomas H
Ullenhag, Gustav
Article History
Received: 8 September 2015
Revised: 13 January 2016
Accepted: 1 February 2016
First Online: 31 March 2016
Competing interests
: Dr Loskog is the CEO and board member of Lokon Pharma AB, the chairman of Vivolux AB and RePos Pharma AB, a scientific advisor at NEXTTOBE AB and has a royalty agreement with Alligator Bioscience AB and Lokon Pharma AB. Dr Tötterman and Dr Mangsbo have a royalty agreement with Alligator Bioscience AB and are board members and shareholders in Immuneed AB. Dr Mangsbo was CEO of Immuneed AB and is employed by AstraZeneca AB. Dr Tötterman is an advisor of Alligator Bioscience AB. Dr Ullenhag was a Medical Advisor to Lokon Pharma AB. The remaining authors declare no conflict of interest.